Platform

WHAT IS SPECTA?

WHY SPECTA?

PLATFORM STATUS

OUR HQ TEAM

Projects

VIEW ALL PROJECTS

RP-1920 BIORADON Recruiting 2148-MRD Recruiting RP-1828 IMMUCAN Closed to recruitment – Analysis phase RP-1843 ARCAGEN Closed to recruitment – Analysis phase RP-1759 AYA Closed to Recruitment - Analysis Phase IMMUcan project 3d rendering tumor Arcagen Project DNA Strand and Cancer cell AYA Project Gene therapy for cancer treatment Bioradon project lung cancer xray RP-2148-MRD - Illustration

RP-1920 BIORADON

Recruiting

Activation phase

RP-1828 IMMUCAN

Closed to recruitment – Analysis phase

RP-1843 ARCAGEN

Closed to recruitment – Analysis phase

News

DISCOVER MORE

July 23, 2026 Molecular profiling and access to treatment for rare cancers in Europe - ARCAGEN study final results READ MORE July 15, 2026 New study advances personalised medicine for rare Peritoneal Mesothelioma READ MORE August 4, 2025 2148 MRD Study reaches milestone with First Patient In (FPI) READ MORE October 31, 2024 IMMUcan has completed patient enrolment READ MORE October 5, 2023 Happy 2 year anniversary BioRadon! READ MORE June 2, 2023 IMMUcan reaches 1500 Patients enrolled READ MORE April 26, 2023 300 Patients Registered for the Bioradon Study READ MORE January 9, 2023 2000 Patients Enrolled on the SPECTA Platform READ MORE October 26, 2022 Arcagen project recruitment is now complete READ MORE May 19, 2022 EORTC and Alliance Healthcare’s continued partnership READ MORE

SEARCH OUR NEWSPROJECTS

Join

You would like to join us?

AS AN

INVESTIGATOR

Let’s work together >

AS A

RESEARCHER

Let’s work together >